Diabetes Management in Chronic Liver Disease

Diabetes in the context of chronic liver disease arises from an intricate bidirectional relationship in which hepatic dysfunction promotes impaired glucose regulation and vice versa. Altered insulin clearance, peripheral insulin resistance and dysregulated gluconeogenesis combine to heighten the risk of hepatogenous diabetes in cirrhosis and nonalcoholic fatty liver disease. Conversely, hyperglycaemia and hyperinsulinaemia accelerate fibrogenesis, portal hypertension and the development of hepatocellular carcinoma. Management hinges on a personalised balance between lifestyle measures—tailored nutritional counselling and graded exercise—and pharmacotherapy selected according to liver‐specific safety profiles. Metformin remains first‐line in compensated disease, whereas insulin and newer agents such as glucagon‐like peptide-1 receptor agonists or sodium-glucose co-transporter-2 inhibitors are introduced with caution, mindful of altered pharmacokinetics and risk of hypoglycaemia or lactic acidosis. Regular assessment of glycaemic control, liver function and potential complications guides dose adjustments, while transplant considerations demand close collaboration between endocrinologists and hepatologists. Globally, the mounting prevalence of diabetes in chronic liver disease underscores the urgency of integrated care pathways to improve outcomes.

Research from Nature Portfolio

Continuous glucose monitoring has revealed divergent patterns of glycaemic variability across different aetiologies of chronic liver disease. In patients with nonalcoholic fatty liver disease, measures of postprandial peaks and overall glucose excursion amplitude were closely linked to the severity of hepatic fibrosis. By contrast, in chronic viral hepatitis, pronounced glycaemic swings emerged in parallel with hypoalbuminaemia rather than fibrosis markers. These findings emphasise the value of high-resolution glucose profiling for tailoring glycaemic targets and therapeutic intensity according to underlying liver pathology.

Diabetes Management in Chronic Liver Disease publication trend

The graph below shows the total number of articles in diabetes management in chronic liver disease across all publications each year (not limited to Nature Index journals).

Technical terms

Hepatogenous diabetes: Impaired glucose regulation arising directly from chronic liver dysfunction rather than primary pancreatic β-cell failure.

Insulin resistance: A state in which target tissues (liver, muscle, adipose) respond inadequately to normal circulating insulin levels, leading to hyperglycaemia.

Continuous glucose monitoring (CGM): A device-based system that provides real-time measurements of interstitial glucose to capture daily glycaemic patterns and variability.

Glycaemic variability: The degree of fluctuation in blood glucose concentration over hours to days, encompassing both hyperglycaemic peaks and hypoglycaemic troughs.

FIB-4 and APRI: Composite biochemical scores using routine laboratory parameters to estimate the extent of hepatic fibrosis non-invasively.

References

1. Assessment of hepatic fibrosis with non-invasive indices in subjects with diabetes before and after liver transplantation. Frontiers in Endocrinology (2024).
2. Insulin Resistance across the Spectrum of Nonalcoholic Fatty Liver Disease. Metabolites (2021).
3. Differences in characteristics of glucose intolerance between patients with NAFLD and chronic hepatitis C as determined by CGMS. Scientific Reports (2017).
4. Management of Diabetes Mellitus in Patients with Chronic Liver Diseases. Journal of Diabetes Research (2019).
5. Is insulin the preferred treatment in persons with type 2 diabetes and liver cirrhosis?. BMC Gastroenterology (2021).